Advances in the treatment of interstitial cystitis

Expert Opinion on Pharmacotherapy
C Lowell Parsons

Abstract

Recent years have brought dramatic advances in the clinician's ability to offer effective pharmacotherapy to patients who have interstitial cystitis. Medical treatments have been developed and applied to reduce the interstitial cystitis symptoms of pelvic pain and urinary urgency/frequency, and to address underlying causes of the disorder. In addition, advances in the understanding of the natural history of interstitial cystitis have revealed that it is insidiously progressive and the classical definition--rare, severe and difficult to treat--is in fact the relatively uncommon, advanced stage of a disorder that affects most individuals in a mild-to-moderate and readily treatable form. This recognition has led to the identification of large numbers of previously unsuspected cases of interstitial cystitis, and the successful treatment of many individuals in the early stages of interstitial cystitis when it is far more responsive to therapy. A heparinoid-based multimodal medical regimen can effectively control symptoms and address disease pathophysiology in the majority of cases. Intravesical therapeutic solutions are new and promising adjunctive therapies that can offer immediate symptom relief during symptom flares, and for pati...Continue Reading

References

Sep 1, 1987·The Journal of Urology·C L Parsons, S G Mulholland
Apr 1, 1989·The Journal of Urology·P M HannoA J Wein
May 1, 1994·British Journal of Urology·C L ParsonsD Lebow
Mar 1, 1993·The Journal of Urology·J A KoziolE M Tan
Mar 7, 2002·Urology·C Lowell ParsonsUNKNOWN Elmiron Study Group
Nov 20, 2002·American Journal of Obstetrics and Gynecology·C Lowell ParsonsJohn J Willems
Aug 13, 2003·The Journal of Urology·G R SantUNKNOWN Interstitial Cystitis Clinical Trials Group
Nov 10, 2004·Urology·C Lowell Parsons, Vasiliki Tatsis
Mar 11, 2005·The Journal of Urology·C Lowell ParsonsGita Singh
Mar 11, 2005·The Journal of Urology·Robert MayerUNKNOWN Interstitial Cystitis Clinical Trials Group
Apr 9, 2005·International Urogynecology Journal and Pelvic Floor Dysfunction·Tony Y H ChenLe Mai Tu
Apr 12, 2005·The Journal of Urology·Christopher K PayneUNKNOWN ICOS RTX Study Group (Resiniferatoxin Treatment for Interstitial Cystitis)
May 21, 2005·Journal of Minimally Invasive Gynecology·Edward J StanfordAnne Feng
Oct 12, 2005·The Journal of Urology·Arndt van Ophoven, Lothar Hertle
Nov 11, 2005·The Journal of Urology·Matt T Rosenberg, Matthew Hazzard
Feb 1, 1949·The Journal of Urology·J R HAND

❮ Previous
Next ❯

Citations

Jan 1, 2007·Women's Health·Kaytan V Amrute, Robert M Moldwin
Dec 20, 2011·The Journal of Urology·Charles N RudickDavid J Klumpp
Mar 18, 2009·Neurourology and Urodynamics·Simone D GueriosDale E Bjorling
Nov 19, 2014·PloS One·Charles N RudickDavid J Klumpp
Feb 22, 2008·American Journal of Physiology. Regulatory, Integrative and Comparative Physiology·Charles N RudickPraveen Thumbikat
Sep 5, 2008·Nature Clinical Practice. Urology·David J Klumpp, Charles N Rudick
Jul 13, 2007·American Journal of Physiology. Regulatory, Integrative and Comparative Physiology·Charles N RudickDavid J Klumpp

❮ Previous
Next ❯

Related Concepts

Trending Feeds

COVID-19

Coronaviruses encompass a large family of viruses that cause the common cold as well as more serious diseases, such as the ongoing outbreak of coronavirus disease 2019 (COVID-19; formally known as 2019-nCoV). Coronaviruses can spread from animals to humans; symptoms include fever, cough, shortness of breath, and breathing difficulties; in more severe cases, infection can lead to death. This feed covers recent research on COVID-19.

Blastomycosis

Blastomycosis fungal infections spread through inhaling Blastomyces dermatitidis spores. Discover the latest research on blastomycosis fungal infections here.

Nuclear Pore Complex in ALS/FTD

Alterations in nucleocytoplasmic transport, controlled by the nuclear pore complex, may be involved in the pathomechanism underlying multiple neurodegenerative diseases including Amyotrophic Lateral Sclerosis and Frontotemporal Dementia. Here is the latest research on the nuclear pore complex in ALS and FTD.

Applications of Molecular Barcoding

The concept of molecular barcoding is that each original DNA or RNA molecule is attached to a unique sequence barcode. Sequence reads having different barcodes represent different original molecules, while sequence reads having the same barcode are results of PCR duplication from one original molecule. Discover the latest research on molecular barcoding here.

Chronic Fatigue Syndrome

Chronic fatigue syndrome is a disease characterized by unexplained disabling fatigue; the pathology of which is incompletely understood. Discover the latest research on chronic fatigue syndrome here.

Evolution of Pluripotency

Pluripotency refers to the ability of a cell to develop into three primary germ cell layers of the embryo. This feed focuses on the mechanisms that underlie the evolution of pluripotency. Here is the latest research.

Position Effect Variegation

Position Effect Variagation occurs when a gene is inactivated due to its positioning near heterochromatic regions within a chromosome. Discover the latest research on Position Effect Variagation here.

STING Receptor Agonists

Stimulator of IFN genes (STING) are a group of transmembrane proteins that are involved in the induction of type I interferon that is important in the innate immune response. The stimulation of STING has been an active area of research in the treatment of cancer and infectious diseases. Here is the latest research on STING receptor agonists.

Microbicide

Microbicides are products that can be applied to vaginal or rectal mucosal surfaces with the goal of preventing, or at least significantly reducing, the transmission of sexually transmitted infections. Here is the latest research on microbicides.